Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Report Overview
Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer’s disease patients.
The Gamma Secretase (EC 3.4.23.) pipeline drugs market research report provides comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are central nervous system, oncology, ear nose throat disorders, non malignant disorders, cardiovascular, genetic disorders, and metabolic disorders. Central nervous system dominates the pipeline market.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Therapy Areas
For more Gamma Secretase (EC 3.4.23.) pipeline drugs market therapy areas insights, download a free report sample
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Gamma Secretase Inhibitor, Gamma Secretase Modulator, Presenilin 1 Inhibitor, and Presenilin 1 Activator. Gamma Secretase Inhibitor is the leading mechanism of action in the Gamma Secretase (EC 3.4.23.) pipeline drugs market.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Mechanisms of Action
For more Gamma Secretase (EC 3.4.23.) pipeline drugs market mechanisms of action insights, download a free report sample
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are oral, intravenous, and intratympanic. Most of the drugs are administered through the oral route.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Routes of Administration
For more Gamma Secretase (EC 3.4.23.) pipeline drugs market routes of administration insights, download a free report sample
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are small molecule, gene therapy, and peptide. Small molecule is the leading molecule type in the Gamma Secretase (EC 3.4.23.) pipeline drugs market.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Molecule Types
For more Gamma Secretase (EC 3.4.23.) pipeline drugs market molecule types insights, download a free report sample
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market – Competitive Landscape
Some of the leading companies in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Adipo Therapeutics, AlzeCure Pharma AB, Astellas Pharma Inc, Audion Therapeutics BV, Ayala Pharmaceuticals Inc, Eli Lilly and Co, Everfront Biotech Inc, F. Hoffmann-La Roche Ltd, Laminar Pharmaceuticals SA, and Merck & Co Inc. Ayala Pharmaceuticals Inc is the leading company in the pipeline market.
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Companies
To know more about the leading players in the Gamma Secretase (EC 3.4.23.) pipeline drugs market, download a free report sample
Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Report Overview
| Key Therapy Areas | Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular, Genetic Disorders, and Metabolic Disorders |
| Key Mechanisms of Action | Gamma Secretase Inhibitor, Gamma Secretase Modulator, Presenilin 1 Inhibitor, and Presenilin 1 Activator |
| Key Routes of Administration | Oral, Intravenous, and Intratympanic |
| Key Molecule Types | Small Molecule, Gene Therapy, and Peptide |
| Leading Companies | Adipo Therapeutics, AlzeCure Pharma AB, Astellas Pharma Inc, Audion Therapeutics BV, Ayala Pharmaceuticals Inc, Eli Lilly and Co, Everfront Biotech Inc, F. Hoffmann-La Roche Ltd, Laminar Pharmaceuticals SA, and Merck & Co Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.).
- The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects.
- The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Laminar Pharmaceuticals SA
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Gamma Secretase (EC 3.4.23.) pipeline drugs market?
The key therapy areas in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular, Genetic Disorders, and Metabolic Disorders.
-
What are the key mechanisms of action in the Gamma Secretase (EC 3.4.23.) pipeline drugs market?
The key mechanisms of action in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Gamma Secretase Inhibitor, Gamma Secretase Modulator, Presenilin 1 Inhibitor, and Presenilin 1 Activator.
-
What are the key routes of administration in the Gamma Secretase (EC 3.4.23.) pipeline drugs market?
The key routes of administration in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Oral, Intravenous, and Intratympanic.
-
What are the key molecule types in the Gamma Secretase (EC 3.4.23.) pipeline drugs market?
The key molecule types in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Small Molecule, Gene Therapy, and Peptide.
-
Which are the leading companies in the Gaucher Disease pipeline products market?
Some of the leading companies in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Adipo Therapeutics, AlzeCure Pharma AB, Astellas Pharma Inc, Audion Therapeutics BV, Ayala Pharmaceuticals Inc, Eli Lilly and Co, Everfront Biotech Inc, F. Hoffmann-La Roche Ltd, Laminar Pharmaceuticals SA, and Merck & Co Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports